<p>PKS Advisory Services LLC 在最近向美国证券交易委员会（SEC）披露的信息中表示，在第二季度其在礼来公司的持股增加了 53.8%。该基金在此期间购买了 326 股后，持有该公司 932 股股票。根据其最近的 SEC 文件，PKS Advisory Services LLC 在礼来公司的持股价值为 726,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>HIMS 的股价波动如过山车。投资者应该入场吗？</li>
</ul>
<p>其他一些对冲基金最近也对其在 LLY 的持仓进行了调整。Lazard Freres Gestion S.A.S. 在第二季度将其在礼来公司的股份增加了 114.3%。Lazard Freres Gestion S.A.S. 目前持有 77,295 股该公司的股票，价值 60,253,000 美元，此前在上个季度又购买了 41,222 股。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的持股增加了 15.3%。Precedent Wealth Partners LLC 目前持有 294 股该公司的股票，价值 229,000 美元，此前在此期间又收购了 39 股。Capital Advisors Inc. OK 在第二季度将其在礼来公司的持仓增加了 6.8%。Capital Advisors Inc. OK 目前持有 6,747 股该公司的股票，价值 5,260,000 美元，此前在上个季度又收购了 429 股。Family CFO Inc 在第二季度购买了礼来公司的新股份，价值约 54,000 美元。最后，Duquesne Family Office LLC 在第一季度将其在礼来公司的持仓增加了 52.5%。Duquesne Family Office LLC 目前持有 94,830 股该公司的股票，价值 78,321,000 美元，此前在上个季度又购买了 32,640 股。82.53% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>几家研究公司最近对 LLY 发表了评论。汇丰银行在 10 月 1 日的研究报告中将礼来公司的目标股价从 700.00 美元上调至 800.00 美元。Weiss Ratings 在 10 月 8 日的报告中重申了对礼来公司的 “持有（c+）” 评级。德意志银行在 8 月 11 日的研究报告中将礼来公司的目标股价从 1,010.00 美元下调至 900.00 美元，并对该股票设定了 “买入” 评级。瑞银集团在 11 月 7 日的研究报告中将礼来公司的目标价从 895.00 美元上调至 1,080.00 美元，并给予该公司 “买入” 评级。最后，Berenberg Bank 在 9 月 17 日的报告中重申了 “持有” 评级，并将礼来公司的目标价设定为 830.00 美元（低于 970.00 美元）。三位分析师对该股票给予了强烈买入评级，十五位给予了买入评级，七位给予了持有评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 1,027.95 美元。</p>
<ul>
<li>诺和诺德年初至今下跌 45%，引发价格战</li>
</ul>
<p><strong>查看我们关于 LLY 的最新研究报告</strong></p>
<h2>礼来公司的股价表现</h2>
<p>礼来公司（NYSE:LLY）周四开盘价为 1,048.90 美元。该公司的市值为 991.61 亿美元，市盈率为 68.56，市盈增长比率为 1.21，贝塔值为 0.43。该公司的 50 日移动平均价格为 844.09 美元，200 日移动平均价格为 784.22 美元。该公司的债务与股本比率为 1.86，速动比率为 1.00，流动比率为 1.28。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,055.59 美元。</p>
<ul>
<li>医疗保健轮动正在进行：3 只股票引领潮流</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日发布了其财报。该公司报告本季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的净利润率为 25.91%，股本回报率为 92.72%。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。礼来公司的季度收入同比增长 53.9%。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。作为一个整体，卖方分析师预计礼来公司在当前财年将发布 23.48 的每股收益。</p>
<h2>礼来公司宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 12 月 10 日（星期三）支付。11 月 14 日（星期五）的登记投资者将获得 1.50 美元的分红。除息日为 11 月 14 日（星期五）。这代表着每年 6.00 美元的分红，收益率为 0.6%。礼来公司的分红支付比率（DPR）目前为 29.35%。</p>
<h2>礼来公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖的 Zepbound。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>FTSE 100 指数是什么？</li>
<li>特斯拉是否在为年末反弹做准备，还是会崩溃？</li>
<li>股票中的死亡交叉是什么？</li>
<li>应用材料：2025 年上涨 40%，长期有增长空间</li>
<li>日经 225 指数是什么？</li>
<li>onsemi 在其自身股票上下注 60 亿美元</li>
</ul>
<p><strong>想看看其他对冲基金持有的 LLY 吗？</strong> 访问 HoldingsChannel.com 获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>PKS Advisory Services LLC 在第二季度将其在礼来的持股增加了 53.8%，持有 932 股，价值 726,000 美元。其他基金也调整了在礼来的持仓。分析师设定了新的价格目标，平均评级为 “适度买入”，目标价格为 1,027.95 美元。礼来的第三季度收益超出预期，收入同比增长 53.9%</p>

<p>PKS Advisory Services LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 53.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 932 shares of the company's stock after purchasing an additional 326 shares during the period. PKS Advisory Services LLC's holdings in Eli Lilly and Company were worth $726,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>PKS Advisory Services LLC 在最近向美国证券交易委员会（SEC）披露的信息中表示，在第二季度其在礼来公司的持股增加了 53.8%。该基金在此期间购买了 326 股后，持有该公司 932 股股票。根据其最近的 SEC 文件，PKS Advisory Services LLC 在礼来公司的持股价值为 726,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 的股价波动如过山车。投资者应该入场吗？</li>
</ul>
</div><p>A number of other hedge funds have also recently made changes to their positions in LLY. Lazard Freres Gestion S.A.S. raised its stake in Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock valued at $60,253,000 after buying an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock worth $229,000 after acquiring an additional 39 shares during the period. Capital Advisors Inc. OK increased its position in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after acquiring an additional 429 shares during the last quarter. Family CFO Inc bought a new position in Eli Lilly and Company in the second quarter valued at about $54,000. Finally, Duquesne Family Office LLC boosted its position in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares during the last quarter. 82.53% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也对其在 LLY 的持仓进行了调整。Lazard Freres Gestion S.A.S. 在第二季度将其在礼来公司的股份增加了 114.3%。Lazard Freres Gestion S.A.S. 目前持有 77,295 股该公司的股票，价值 60,253,000 美元，此前在上个季度又购买了 41,222 股。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的持股增加了 15.3%。Precedent Wealth Partners LLC 目前持有 294 股该公司的股票，价值 229,000 美元，此前在此期间又收购了 39 股。Capital Advisors Inc. OK 在第二季度将其在礼来公司的持仓增加了 6.8%。Capital Advisors Inc. OK 目前持有 6,747 股该公司的股票，价值 5,260,000 美元，此前在上个季度又收购了 429 股。Family CFO Inc 在第二季度购买了礼来公司的新股份，价值约 54,000 美元。最后，Duquesne Family Office LLC 在第一季度将其在礼来公司的持仓增加了 52.5%。Duquesne Family Office LLC 目前持有 94,830 股该公司的股票，价值 78,321,000 美元，此前在上个季度又购买了 32,640 股。82.53% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research firms have recently commented on LLY. HSBC upped their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a &#34;hold (c+)&#34; rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, August 11th. UBS Group boosted their price objective on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, November 7th. Finally, Berenberg Bank reaffirmed a &#34;hold&#34; rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $1,027.95.</p>
<div class="lb-trans"><p>几家研究公司最近对 LLY 发表了评论。汇丰银行在 10 月 1 日的研究报告中将礼来公司的目标股价从 700.00 美元上调至 800.00 美元。Weiss Ratings 在 10 月 8 日的报告中重申了对礼来公司的 “持有（c+）” 评级。德意志银行在 8 月 11 日的研究报告中将礼来公司的目标股价从 1,010.00 美元下调至 900.00 美元，并对该股票设定了 “买入” 评级。瑞银集团在 11 月 7 日的研究报告中将礼来公司的目标价从 895.00 美元上调至 1,080.00 美元，并给予该公司 “买入” 评级。最后，Berenberg Bank 在 9 月 17 日的报告中重申了 “持有” 评级，并将礼来公司的目标价设定为 830.00 美元（低于 970.00 美元）。三位分析师对该股票给予了强烈买入评级，十五位给予了买入评级，七位给予了持有评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 1,027.95 美元。</p>
</div><ul>
<li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德年初至今下跌 45%，引发价格战</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 LLY 的最新研究报告</strong></p>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>礼来公司的股价表现</h2>
</div><p>Shares of NYSE:LLY opened at $1,048.90 on Thursday. The firm has a market cap of $991.61 billion, a price-to-earnings ratio of 68.56, a P/E/G ratio of 1.21 and a beta of 0.43. The firm has a fifty day moving average price of $844.09 and a 200 day moving average price of $784.22. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,055.59.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY）周四开盘价为 1,048.90 美元。该公司的市值为 991.61 亿美元，市盈率为 68.56，市盈增长比率为 1.21，贝塔值为 0.43。该公司的 50 日移动平均价格为 844.09 美元，200 日移动平均价格为 784.22 美元。该公司的债务与股本比率为 1.86，速动比率为 1.00，流动比率为 1.28。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,055.59 美元。</p>
</div><ul>
<li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗保健轮动正在进行：3 只股票引领潮流</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts' consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the firm posted $1.18 earnings per share. Eli Lilly and Company's revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日发布了其财报。该公司报告本季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的净利润率为 25.91%，股本回报率为 92.72%。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。礼来公司的季度收入同比增长 53.9%。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。作为一个整体，卖方分析师预计礼来公司在当前财年将发布 23.48 的每股收益。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<div class="lb-trans"><h2>礼来公司宣布分红</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 12 月 10 日（星期三）支付。11 月 14 日（星期五）的登记投资者将获得 1.50 美元的分红。除息日为 11 月 14 日（星期五）。这代表着每年 6.00 美元的分红，收益率为 0.6%。礼来公司的分红支付比率（DPR）目前为 29.35%。</p>
</div><h2>Eli Lilly and Company Profile</h2>
<div class="lb-trans"><h2>礼来公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖的 Zepbound。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>What is the FTSE 100 index?</li>
<li>Is Tesla Setting Up for a Year-End Rebound—or a Collapse?</li>
<li>What is a Death Cross in Stocks?</li>
<li>Applied Materials: Up 40% in 2025 With Room to Run Long-Term</li>
<li>What is the Nikkei 225 index?</li>
<li>onsemi Places a $6 Billion Bet on Its Own Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>FTSE 100 指数是什么？</li>
<li>特斯拉是否在为年末反弹做准备，还是会崩溃？</li>
<li>股票中的死亡交叉是什么？</li>
<li>应用材料：2025 年上涨 40%，长期有增长空间</li>
<li>日经 225 指数是什么？</li>
<li>onsemi 在其自身股票上下注 60 亿美元</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 LLY 吗？</strong> 访问 HoldingsChannel.com 获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

PKS Advisory Services LLC 增加了在礼来公司（Eli Lilly）的持仓 $LLY